CXCR1 and COVID-19: Compared to the maximum observed in the cohort during the study period, vaccine effectiveness moderately decreased for all schemes and outcomes studied (Fig. 1), although most confidence intervals overlapped, with some exceptions (Supplementary Tables S6 and S7): vaccine effectiveness against COVID-19-related ICU admissions significantly decreased for the CCA scheme, and protection against COVID-19-related deaths significantly decreased for CC+mRNA, CCC, and CCA (Fig. 1 and Supplementary Tables S6 and S7).